Literature DB >> 26312680

Possibly drug-induced palpable migratory arciform erythema.

Fernando Luiz Teixeira Dantas1, Neusa Yuriko Sakai Valente1, Isis Suga Veronez1, Priscila Kakizaki1, Juliana Ribeiro Leitão1, Rafael Cavanellas Fraga1.   

Abstract

Palpable migratory arciform erythema is an entity of unknown etiology, with few published cases in the literature. The clinical and histopathological features of this disease are difficult to be distinguished from those of Jessner's lymphocytic infiltration of the skin, lupus erythematous tumidus and the deep erythema annulare centrifugum. We describe here the first two Brazilian cases of palpable migratory arciform erythema. The patients presented with infiltrated annular plaques and erythematous arcs without scales. These showed centrifugal growth before disappearing without scarring or residual lesions after a few days. They had a chronic course with repeated episodes for years. In addition, these cases provide evidence of a drug-induced etiology.

Entities:  

Mesh:

Year:  2015        PMID: 26312680      PMCID: PMC4540514          DOI: 10.1590/abd1806-4841.20153624

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


INTRODUCTION

Palpable migratory arciform erythema (PMAE) is part of the set of lymphocytic infiltrations of the skin. Histologically, it is characterized by a perivascular and periadnexal T lymphocytic infiltrate. Moreover, it is considered to classify within the spectrum of pseudolymphomas, like Jessner-Kanof 's lymphocytic infiltration of the skin-(JK-LI), with which it shares histopathological features.[1].[2] We report two cases of PMAE, discuss the clinical differences between PMAE, JK-LI, lupus erythematous tumidus (LET) and other dermatoses, and comment on the possibility of PMAE being drug-induced.

CASES REPORT

Case 1:

A 60-year-old female patient had a two-year history of erythematous plaque in the cervical region, with centrifugal growth and central clearing. The plaque spontaneously disappeared after seven to ten days, without scarring. The patient reported burning sensation at the site of the plaque. The lesions progressed, alternating outbreaks and remissions at different sites, such as the chest and back. However, they always show the same pattern, at 20-to-30-day intervals. At the time of consultation, the patient presented with a lesion in the upper limb, which was 8 cm in diameter (Figure 1).
FIGURE 1

case 1 - lesion on the left arm. Arciform, elevated, infiltrated and erythematous plaque with mild erythema in the central area and 8 cm in diameter

case 1 - lesion on the left arm. Arciform, elevated, infiltrated and erythematous plaque with mild erythema in the central area and 8 cm in diameter She was being treated for fibromyalgia and osteoarthritis with clomipramine, nimesulide and paracetamol. Complete blood count, tests of liver and kidney functions all gave results within normal ranges. Antinuclear factor, as well as serology for herpes simplex virus, syphilis, and Borrelia burgdorferi were all negative. The patient underwent incisional biopsy of the arm lesion, which revealed predominantly lymphocytic perivascular and periadnexal dermatitis with eosinophils and neutrophils, and moderate mucin deposition in the dermis (Figure 2).
FIGURE 2

Histopathology of case 1 - hematoxylin-eosin, 400x magnification. Detail of a predominantly lymphocytic, mixed infiltrate with neutrophils and eosinophils in the periadnexal fat

Histopathology of case 1 - hematoxylin-eosin, 400x magnification. Detail of a predominantly lymphocytic, mixed infiltrate with neutrophils and eosinophils in the periadnexal fat Drugs were discontinued. After a few weeks of remission, the lesions reappeared in acral regions (Figure 3).
FIGURE 3

case 1 - acral lesions. Arciform, palpable, erythematous plaques in the hypothenar region of the hand, on the heel and lateral border of the foot

case 1 - acral lesions. Arciform, palpable, erythematous plaques in the hypothenar region of the hand, on the heel and lateral border of the foot

Case 2:

A 47-year-old female patient had a 1-year history of infiltrated, circinate erythematous lesions with elevated borders in the upper limbs, upper back and posterior neck. The lesions spontaneously disappeared after progressive central clearing and an average duration of three weeks. They are recurrent and migratory. (Figure 4) The patient made daily use of statin and consumed dipyrone and diclofenac sporadically. A biopsy of the right arm lesion with revealed lymphocytic perivascular and periadnexal dermatitis (Figure 5). In addition, Alcian Blue staining revealed a moderate amount of mucin deposition. PAS staining showed no thickening of the basement membrane (Figure 6).
FIGURE 4

case 2 - lesion on the right arm. Annular, erythematous, infiltrated and palpable plaques with spared center on the lateral region of the arm

FIGURE 5

Histopathology of case 2 - hematoxylin-eosin, 100x magnifi cation. Mildly acanthotic epidermis. Dermis with perivascular lymphocytic infiltrate and moderate interstitial mucinosis

FIGURE 6

Histopathology of case 2 - OM x 200. Alcian blue staining counter-stained with PAS show moderate interstitial mucin deposition in the reticular dermis

case 2 - lesion on the right arm. Annular, erythematous, infiltrated and palpable plaques with spared center on the lateral region of the arm Histopathology of case 2 - hematoxylin-eosin, 100x magnifi cation. Mildly acanthotic epidermis. Dermis with perivascular lymphocytic infiltrate and moderate interstitial mucinosis Histopathology of case 2 - OM x 200. Alcian blue staining counter-stained with PAS show moderate interstitial mucin deposition in the reticular dermis After 12 weeks of drug discontinuation, there was complete regression of all lesions.

DISCUSSION

PMAE has very different evolution from that of JK-LI. The former leads to the emergence of dynamic skin lesions that increase in size and disappear after a few days. The appearance of new lesions in different areas justifies the use of the term "migratory" This feature is not shared by JK-LI, which presents static lesions that may persist for months to years without migrating to other areas of the body. Another differential feature of PMAE is the fact that the preferred areas of involvement are the back and arms, and less frequently the chest and thighs. There are no reports of cases on the face, the most common site affected by JK-LI.[3].[4] Histopathologic findings show a moderate to severe perivascular and periadnexal T lymphocytic infiltrate with no major epidermal alterations. Inflammatory cells have no interstitial distribution. Plasma cells are absent, which helps differentiate the disease from chronic erythema migrans (ECM). [4] The pathogenesis is unknown and the polyclonality of the infiltrate speaks against a possible neoplastic nature. [2,4] Furthermore, no evidence of infection by Treponema pallidum, Borrelia burgdorferi, and herpes simplex virus was found, which makes the infective hypothesis less likely. As there have been reports of drug-induced JK-LI (by leflunomide, subcutaneous injections of glatiramer acetate and inhibitors of angiotensin-converting enzyme), PMAE could eventually be a drug eruption, since the patients reported here were being treated with various drugs and there is a temporal relationship between the use of these drugs and the appearance of skin lesions. Additionally, we found a reasonable amount of eosinophils in the inflammatory infiltrate of the first patient and vacuolar degeneration of basal cells in the second patient, and the latter showed complete remission of PMAE after drugs discontinuation.[5-7] Current knowledge indicates that drugs may alter immune surveillance, leading to an abnormal activity of T lymphocytes, both in their differentiation and in their proliferation, which would cause cutaneous lymphocytic infiltrates or T lymphocytes pseudolymphomas.[7] The differential diagnosis includes LET, the deep erythema annulare centrifugum (EAC), ECM, granuloma annulare and polymorphous light eruption.[2,4,8] LET is clinically indistinguishable from JK-LI, since both entities share the same age of onset and histopathological findings, and show photosensitivity, absence of extra-cutaneous involvement, and good response to antimalarials. A mild epidermal atrophy appears to be present in the first and not the latter. Moreover, it is known that both may show mucin deposition in the dermis in 50% of cases, which does not help in differentiating between them and PMAE. [9] Deep EAC also has the same clinical and pathological features as JK-LI, LET and PMAE. However, only the latter is characterized by migratory and fleeting lesions, while the others are conspicuous by the presence of lesions that last for months to years. [10] ECM was discarded due to negative serology for B. burgdorferi. Polymorphous light eruption also was also excluded because the lesions developed in non-photo-exposed areas. The hypothesis of granuloma annulare is incompatible with the histopathologic findings of the cases presented here. Treatment of PMAE includes antimicrobials such as penicillin and cefuroxime, topical corticosteroids (either under occlusion or not) and UVA-1 phototherapy, in an attempt to prevent outbreaks or extend the time between them. Unfortunately, most cases tend to recur after weeks, despite treatment attempts.[2,4,8] In this paper, we describe the first two Brazilian cases of PMAE whose etiology involves several hypotheses and to which we add the induction by drugs. In addition, as the number of cases reported in the literature is small, few conclusions can be made. Further studies might show whether PMAE, JK-LI, LET and the deep EAC are part of a continuous spectrum of clinical variants of the same entity.
  10 in total

1.  Lymphocytic infiltration of the skin.

Authors:  A J ORFUSS
Journal:  AMA Arch Derm Syphilol       Date:  1953-10

2.  ACE-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and Lupus erythematosus tumidus.

Authors:  Carmelo Schepis; Maria Lentini; Maddalena Siragusa; Dario Batolo
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

3.  Palpable migratory arciform erythema. Clinical morphology, histopathology, immunohistochemistry, and response to treatment.

Authors:  D Abeck; M W Ollert; F Eckert; R M Szeimies; M Tiemann; O Braun-Falco; V Steinkraus; J Ring
Journal:  Arch Dermatol       Date:  1997-06

4.  [Palpable arciforme migratory erythema].

Authors:  G Wagner; S Bartsch; C Rose; M M Sachse
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

5.  Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate.

Authors:  S Nolden; C Casper; A Kuhn; H F Petereit
Journal:  Mult Scler       Date:  2005-04       Impact factor: 6.312

6.  [Palpable migratory acriform erythema and lymphocytic infiltration of the skin--different presentations of the same entity?].

Authors:  A Steinmann; M Gummer; M Agathos; R Breit
Journal:  Hautarzt       Date:  1999-04       Impact factor: 0.751

7.  [Erythema migrans arciforme et palpabile (T-cell pseudolymphoma)].

Authors:  I Lohrisch; E Alexandrakis; H Maywurm; J Petres
Journal:  Hautarzt       Date:  1990-02       Impact factor: 0.751

8.  Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?

Authors:  Laëtitia Sparsa; Naji Afif; Joëlle Goetz; Christelle Sordet; Emmanuel Chatelus; Dan Lipsker; Jean Sibilia
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

9.  Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases.

Authors:  Valérie Rémy-Leroux; Fabienne Léonard; Daniel Lambert; Janine Wechsler; Bernard Cribier; Pierre Thomas; Henri Adamski; Marie-Claude Marguery; François Aubin; Dominique Leroy; Philippe Bernard
Journal:  J Am Acad Dermatol       Date:  2007-12-20       Impact factor: 11.527

10.  Erythema annulare centrifugum: deep variant with vasculitis like histopathology.

Authors:  Sudhir Uk Nayak; Shrutakirthi D Shenoi; Smitha M Prabhu
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.